The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001796:Blood Protein Disorders / Q000150:complications; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D005260:Female; D006016:Glycolates / Q000494:pharmacology*; D006073:Gout / Q000378:metabolism*; D006218:Halofenate / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008074:Lipoproteins / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010919:Placebos; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood* / Q000652:urine*
D000924:Anticholesteremic Agents; D006016:Glycolates; D000960:Hypolipidemic Agents; D008074:Lipoproteins; D010919:Placebos; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; D003404:Creatinine; D006218:Halofenate